See the DrugPatentWatch profile for Verkazia
What is Verkazia, and what does “peak sales of about 40 million annually” mean?
Verkazia (ciclosporin topical ophthalmic solution) is a medicine used for ocular surface inflammatory disease. When people cite an expectation of around $40 million in “peak sales annually,” they’re referring to a forecast that, at its highest annual sales level, the product could reach roughly that revenue per year. This is a commercial forecasting metric used in investment and market-access discussions, not a regulator-defined milestone.
Which companies and markets matter most for reaching those peak sales?
In practice, peak-sales forecasts like “about 40 million in peak sales annually” usually depend on:
- Country-by-country reimbursement and prescribing uptake across Europe and Asia.
- How quickly regulators approve the product in additional indications or geographies.
- Competition from other dry eye / ocular inflammation therapies and how clinicians position ciclosporin vs alternatives.
Why can sales forecasts differ from real-world outcomes?
Forecasts commonly miss or overestimate outcomes because of:
- Different reimbursement rules by country (coverage, prior authorization, step therapy).
- The speed of formulary listing in national health systems.
- Patient selection and real-world treatment patterns.
- Competitive dynamics once other similar therapies gain access.
When will peak sales typically be reached (and what drives timing)?
Peak sales timing usually reflects how long it takes for:
- Uptake to ramp after launch and initial reimbursement approvals.
- Prescribers to adopt the product for the target patient populations.
- Additional marketing or access expansions to occur in new countries within Europe and Asia.
How can you verify claims about peak sales and forecasted revenue?
The fastest way to check whether a specific forecast (such as ~$40 million annual peak sales) is cited in market-tracker or investor materials is to look for the underlying source that made the estimate. One place often used for product-market and patent/exclusivity research is DrugPatentWatch.com, which compiles information that can include market and lifecycle context for branded drugs (including where available and lifecycle events) [1].
1